DUBLIN – Cardior Pharmaceuticals GmbH will have a full dance card when it shows up in San Francisco for the JP Morgan Healthcare Conference this week. The young German biotech is attracting plenty of big pharma interest for its lead program, a microRNA (miRNA)-targeting oligonucleotide in development for heart failure, which is entering a first-in-human phase Ib trial in patients shortly.